Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
Returns on capital
Orchestra BioMed Holdings, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-83.2%
avg -54.7%
ROIC
-52.4%
avg -165.4%
ROA
-45.9%
avg -73.2%
Analysis
ROA is currently the strongest return metric at -45.9% versus its period average of -73.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer | USD 1.18M | 51 | — | — |
Darren R. Sherman | Founder, President, Chief Operating Officer & Director | USD 1.04M | 55 | — | — |
Andrew Lawrence Taylor | Chief Financial Officer | USD 766.68K | 55 | 590.99K | 0.99% |
Yuval Hay Mika D.Sc | GM & Chief Technology Officer of Bioelectronic Therapies | — | 67 | — | — |
Bob Laughner | Senior Vice President of Regulatory & Quality | — | — | — | — |
William Reed Little | Executive Vice President of Corporate Development & Strategy | — | 55 | 307.86K | 0.51% |
Avraham Matityahu Fischer | Senior Vice President of Medical Affairs & Innovation | — | 70 | — | — |
Hans-Peter Stoll | Senior Vice President & Medical Director | — | — | — | — |
Juan Lorenzo | Senior Vice President of Product Development | — | — | — | — |
Lisa Daniels | Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
13
$6.49M
Sells
7
$439,182.16
Net Transaction Value
+$6.05M
Net buying
Most Active
Sherman Darren
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 9, 26Nov 9, 2026 | RTW INVESTMENTS, LP Indirect | Buy | $6M$6,000,000.00 |
| Nov 9, 26Nov 9, 2026 | Fain Eric S Indirect | Buy | $100K$100,000.00 |
| Nov 9, 26Nov 9, 2026 | Pacitti David Direct | Buy | $100K$100,000.00 |
| Nov 9, 26Nov 9, 2026 | Hochman David P Indirect | Buy | $25K$25,000.00 |
| Nov 9, 26Nov 9, 2026 | Taylor Andrew Lawrence Direct | Buy | $5K$5,000.00 |
| Nov 2, 26Nov 2, 2026 | Sherman Darren Direct | Sell | $86.1K$86,100.00 |
| Oct 1, 26Oct 1, 2026 | Sherman Darren Direct | Sell | $95.4K$95,400.00 |
| Sep 3, 26Sep 3, 2026 | Hochman David P Direct | Buy | $47.9K$47,900.00 |
| Sep 1, 26Sep 1, 2026 | Sherman Darren Direct | Sell | $74.1K$74,100.00 |
| Aug 26, 26Aug 26, 2026 | Sherman Darren Indirect | Buy | $10.7K$10,660.00 |
1–10 of 20
Summary
Insiders reported 13 buys worth $6.49M and 7 sells worth $439,182.16 over the last 12 months. That adds up to net buying of $6.05M. Sherman Darren was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +111.6% | +25.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +111.6% over three years. Forward estimates point to Revenue at +25.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Orchestra BioMed Holdings, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OBIO's management, answered from reported figures.
Who manages OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) lists 10 active executives. The top listed executive is Yuval Hay Mika D.Sc, GM & Chief Technology Officer of Bioelectronic Therapies.
Are OBIO insiders buying or selling?
Recent insider activity shows net buying of $11.99M.
Continue the stock analysis
Jump to another research area for this company.